aGRFS and CRFS. The survival curves are unadjusted, whereas the HRs represent adjusted analyses. (A) The aGRFS was comparable across donor sources. (B) The unadjusted CRFS was better in the omidubicel and UCB arms. Shown are the proportions with aGRFS and CRFS over ∼36 months of overlapping posttransplant follow-up across trial arms and CIBMTR cohorts. HRs are based on analyses over the entirety of available follow-up for all study cohorts. One additional acute GRFS event in the UCB arm and 2 additional chronic GRFS events in the omidubicel arm were observed after 36 months. Haplo, haploidentical.